Investment Landscape: Dementia with Lewy Bodies covers the current R&D investment,
clinical trial pipeline, and funding trends for Dementia with Lewy Bodies research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 0
Active Trials (Recruiting/Active): 0
Dementia with Lewy bodies (DLB) has 0 total clinical trials, representing an underserved area in neurodegenerative research. The small Phase 3 portfolio (0 trials) reflects diagnostic challenges and overlap with Parkinson's and Alzheimer's. DLB represents the second most common neurodegenerative dementia after AD.
DLB research is benefiting from advances in alpha-synuclein PET imaging and DLB-specific biomarkers. The overlap with Parkinson's disease dementia is enabling cross-disease therapeutic development. Cholinergic modulation remains the primary symptomatic approach, but disease-modifying therapies targeting alpha-synuclein aggregation are emerging.
Only 0.0% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01